JP2023514407A5 - - Google Patents

Info

Publication number
JP2023514407A5
JP2023514407A5 JP2022550184A JP2022550184A JP2023514407A5 JP 2023514407 A5 JP2023514407 A5 JP 2023514407A5 JP 2022550184 A JP2022550184 A JP 2022550184A JP 2022550184 A JP2022550184 A JP 2022550184A JP 2023514407 A5 JP2023514407 A5 JP 2023514407A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cells
immune cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514407A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019362 external-priority patent/WO2021173630A1/en
Publication of JP2023514407A publication Critical patent/JP2023514407A/ja
Publication of JP2023514407A5 publication Critical patent/JP2023514407A5/ja
Pending legal-status Critical Current

Links

JP2022550184A 2020-02-24 2021-02-24 増強された活性を有するbcma car-t細胞 Pending JP2023514407A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062980914P 2020-02-24 2020-02-24
US62/980,914 2020-02-24
US202063020713P 2020-05-06 2020-05-06
US63/020,713 2020-05-06
US202063053409P 2020-07-17 2020-07-17
US63/053,409 2020-07-17
US202063092681P 2020-10-16 2020-10-16
US63/092,681 2020-10-16
PCT/US2021/019362 WO2021173630A1 (en) 2020-02-24 2021-02-24 Bcma car-t cells with enhanced activities

Publications (2)

Publication Number Publication Date
JP2023514407A JP2023514407A (ja) 2023-04-05
JP2023514407A5 true JP2023514407A5 (cg-RX-API-DMAC7.html) 2024-03-04

Family

ID=75108802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550184A Pending JP2023514407A (ja) 2020-02-24 2021-02-24 増強された活性を有するbcma car-t細胞

Country Status (15)

Country Link
US (1) US12036243B2 (cg-RX-API-DMAC7.html)
EP (1) EP4110805A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023514407A (cg-RX-API-DMAC7.html)
KR (1) KR20220145846A (cg-RX-API-DMAC7.html)
CN (1) CN115175929A (cg-RX-API-DMAC7.html)
AU (1) AU2021227191A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016657A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167065A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011684A2 (cg-RX-API-DMAC7.html)
IL (1) IL295470A (cg-RX-API-DMAC7.html)
MX (1) MX2022010340A (cg-RX-API-DMAC7.html)
PE (1) PE20221757A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552033A1 (cg-RX-API-DMAC7.html)
TW (1) TWI894211B (cg-RX-API-DMAC7.html)
WO (1) WO2021173630A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230138428A1 (en) * 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
KR20230171994A (ko) 2021-04-16 2023-12-21 셀진 코포레이션 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
EP4499680A1 (en) * 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN117126856A (zh) * 2022-05-20 2023-11-28 上海雅科生物科技有限公司 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
CN119836438A (zh) * 2022-09-19 2025-04-15 艾洛基治疗公司 B-细胞成熟抗原(bcma)抗独特型抗体
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
US20260108629A1 (en) * 2024-08-14 2026-04-23 Kite Pharma, Inc. Vectors for production of therapeutic constructs

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1998002558A2 (en) 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO2007075899A2 (en) 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
WO2011069004A1 (en) * 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
AU2015330017A1 (en) 2014-10-07 2017-04-27 Cellectis Method for modulating car-induced immune cells activity
EP3234145B1 (en) 2014-12-15 2019-06-05 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
TWI700298B (zh) * 2015-04-13 2020-08-01 美商輝瑞股份有限公司 靶向b細胞成熟抗原之嵌合型抗原受體類
WO2016168612A1 (en) 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2018161064A1 (en) 2017-03-03 2018-09-07 F1 Oncology, Inc. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
WO2019055946A1 (en) 2017-09-18 2019-03-21 F1 Oncology, Inc. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF
CN118546961A (zh) * 2016-08-26 2024-08-27 贝勒医学院 用于细胞治疗的组成型活性细胞因子受体
US11654158B2 (en) 2016-11-17 2023-05-23 2Seventy Bio, Inc. TGFBeta signal convertor
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201702617D0 (en) 2017-02-17 2017-04-05 Autolus Ltd Receptor
SG11201908929VA (en) * 2017-03-31 2019-10-30 Univ Leland Stanford Junior Synthekine compositions and methods of use
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
AU2019227979B2 (en) * 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
CN112533942A (zh) * 2018-06-01 2021-03-19 华盛顿大学 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
CN112368298A (zh) 2018-06-22 2021-02-12 凯德药业股份有限公司 嵌合跨膜蛋白及其用途
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
IL328846A (en) 2019-03-01 2026-08-01 Allogene Therapeutics Inc Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases
IL285941B1 (en) 2019-03-01 2026-08-01 Allogene Therapeutics Inc Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN

Similar Documents

Publication Publication Date Title
JP7836847B2 (ja) 二重特異性キメラ抗原受容体およびその治療的使用
JP2023139070A5 (cg-RX-API-DMAC7.html)
CN111527109B (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
JP2020096630A5 (cg-RX-API-DMAC7.html)
US9868961B2 (en) Methods and compositions for localized secretion of anti-CTLA-4 antibodies
CN112074278B (zh) Bcma-car-t细胞
CA2926267C (en) Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
JP2022506598A5 (cg-RX-API-DMAC7.html)
JP2014532074A5 (cg-RX-API-DMAC7.html)
JP2022512882A5 (cg-RX-API-DMAC7.html)
JP2020512019A5 (cg-RX-API-DMAC7.html)
AU2016313107A1 (en) Conditionally active chimeric antigen receptors for modified T-cells
JP2022521240A5 (cg-RX-API-DMAC7.html)
CA3177234A1 (en) Fully humanized bispecific chimeric antigen receptor targeting cd19 and cd22 and use thereof
JP2019536469A5 (cg-RX-API-DMAC7.html)
KR20240004680A (ko) 키메라 수용체 및 이의 사용 방법
JP2023553049A (ja) Cd19+、cd20+、若しくはcd22+腫瘍又はb細胞由来の自己免疫疾患を治療するためのcar t細胞
CN110938148A (zh) 靶向cd19和cd22嵌合抗原受体
JP7619682B2 (ja) Cd22に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体
WO2017195749A1 (ja) キメラ抗原受容体、及びその利用
KR20230143108A (ko) Cd30 유래의 세포내 신호전달 도메인을 포함하는 키메라 항원 수용체, 이를 발현하는 면역세포 및 이들의 용도
EP4301402A1 (en) Bispecific antibodies enhancing cell mediated immune responses
WO2023016554A1 (zh) 靶向cd22的抗原结合蛋白及其用途
US20220144953A1 (en) Vista-binding antibodies and uses thereof
TW202540184A (zh) 一種靶向cd7的人源化抗體、嵌合抗原受體及其應用